Open Access Full Text Article

## CORRIGENDUM

## Evaluation of α-Synuclein and Apolipoprotein E as Potential Biomarkers in Cerebrospinal Fluid to Monitor Pharmacotherapeutic Efficacy in Dopamine Dictated Disease States of Parkinson's Disease and Schizophrenia [Corrigendum]

Gupta AK, Pokhriyal R, Das U, et al. Neuropsychiatr Dis Treat. 2019;15:2073-2085.

The authors wish to advise of typographical errors in Figures 1 and 2 and Table 3, the correct unit of apolipoprotein E concentration is  $\mu g/ml$ , and not pg/ml.

Page 2077, Figure 1A, y axis, the text "CSF apolipoprotein E (pg/ml)" should read "CSF apolipoprotein E (µg/ml)".

Page 2077, Figure 2, x axis, the text "CSF apolipoprotein E (pg/ml)" should read "CSF apolipoprotein E (µg/ml)".

Page 2079, Table 3, Cut-off values to differentiate neurological controls from the disease column, Apolipoprotein E and Apolipoprotein E or  $\alpha$ -synuclein rows, the text ">3.4 pg (Parkinson's disease)" should read ">3.4 µg (Parkinson's disease)" and "<2.6 µg (Schizophrenia)" should read "<2.6 µg (Schizophrenia)".

The authors apologize for these errors and any inconvenience.

Neuropsychiatric Disease and Treatment

**Dove**press

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

https://doi.org/10.2147/NDT.S379262

Received: 20 June 2022 Accepted: 20 June 2022 Published: 27 June 2022 Neuropsychiatric Disease and Treatment 2022:18 1271

1271

© 2022 Gupta et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. by and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).